“Medicaid programs will likely face major budget impacts from emerging cell and gene therapies.”
Amelia Nell
Associate
0%
of Medicare patients with breast cancer taking a medicine covered by Medicare Part B received a therapy that was not routinely covered by England’s NHS or its CDF.